STAT

Opinion: Getting past the bad blood of Theranos through collaboration

The Theranos saga comes with a silver lining — a recognition that liquid biopsies are going to take commitment and collaboration.
Source: Kristoffer Tripplaar/AP

This week’s news that the Securities and Exchange Commission charged Theranos and with fraud put the troubles of the company back into the spotlight. For those of us in the field of liquid biopsy, Theranos has cast a long and persistent shadow on what’s clearly one of the most promising areas in cancer care — using blood tests to improve detection, diagnosis, and treatment and, more broadly, advancing the reality of precision medicine in cancer.

You're reading a preview, sign up to read more.

More from STAT

STAT5 min read
‘What’s My Real Identity?’: As DNA Ancestry Sites Gather More Data, The Answer For Consumers Often Changes
‘What’s my real identity?’: As DNA ancestry sites gather more data, shifting results are causing genetic whiplash.
STAT1 min readScience
Watch: How Did The Amyloid Hypothesis Go From Promising To Perilous In The Search For Alzheimer’s Treatments?
How did nearly two decades of failure not convince the brightest minds in science that it was time to move beyond the leading theory about #Alzheimers?
STAT4 min readTech
Google’s AI Improves Accuracy Of Lung Cancer Diagnosis, Study Shows
In early testing, Google's #artificialintelligence system outperformed six radiologists in diagnosing lung cancer from reviewing a single CT scan.